Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer (2015)
- Authors:
- Mackey, John R.
- Ramos-Vazquez, Manuel
- Oleg Lipatov,
- McCarthy, Nicole
- Krasnozhon, Dmitriy
- Semiglazov, Vladimir
- Manikhas, Alexey
- Gelmon, Karen A.
- Konecny, Gottfried E.
- Webster, Marc
- Hegg, Roberto
- Verma, Sunil
- Gorbunova, Vera
- Gerges, Dany Abi
- Thireau, Francois
- Fung, Helena
- Simms, Lorinda
- Buyse, Marc
- Ibrahim, Ayman
- Martin, Miguel
- Autor USP: HEGG, ROBERTO - FM
- Unidade: FM
- DOI: 10.1200/JCO.2014.57.1513
- Subjects: NEOPLASIAS MAMÁRIAS; TRATAMENTO (RESULTADOS); METÁSTASE NEOPLÁSICA; ANTINEOPLÁSICOS (CLASSIFICAÇÃO)
- Language: Inglês
- Imprenta:
- Source:
- Título: Journal of Clinical Oncology
- ISSN: 0732-183X
- Volume/Número/Paginação/Ano: v. 33, n. 2, p. 141-148, 2015
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
MACKEY, John R. et al. Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer. Journal of Clinical Oncology, v. 33, n. 2, p. 141-148, 2015Tradução . . Disponível em: https://doi.org/10.1200/JCO.2014.57.1513. Acesso em: 24 jan. 2026. -
APA
Mackey, J. R., Ramos-Vazquez, M., Oleg Lipatov,, McCarthy, N., Krasnozhon, D., Semiglazov, V., et al. (2015). Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer. Journal of Clinical Oncology, 33( 2), 141-148. doi:10.1200/JCO.2014.57.1513 -
NLM
Mackey JR, Ramos-Vazquez M, Oleg Lipatov, McCarthy N, Krasnozhon D, Semiglazov V, Manikhas A, Gelmon KA, Konecny GE, Webster M, Hegg R, Verma S, Gorbunova V, Gerges DA, Thireau F, Fung H, Simms L, Buyse M, Ibrahim A, Martin M. Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer [Internet]. Journal of Clinical Oncology. 2015 ; 33( 2): 141-148.[citado 2026 jan. 24 ] Available from: https://doi.org/10.1200/JCO.2014.57.1513 -
Vancouver
Mackey JR, Ramos-Vazquez M, Oleg Lipatov, McCarthy N, Krasnozhon D, Semiglazov V, Manikhas A, Gelmon KA, Konecny GE, Webster M, Hegg R, Verma S, Gorbunova V, Gerges DA, Thireau F, Fung H, Simms L, Buyse M, Ibrahim A, Martin M. Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer [Internet]. Journal of Clinical Oncology. 2015 ; 33( 2): 141-148.[citado 2026 jan. 24 ] Available from: https://doi.org/10.1200/JCO.2014.57.1513 - Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
- Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial
- Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC)
- Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
- Hormonioterapia neoadjuvante no câncer de mama
- Superexpressao do oncogene her-2/neu em carcinomas de mama: analise clinica e imunohistoquimica
- Tratamento neoadjuvante no câncer de mama
- Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
- Terapia estrogenica e cancer de mama
Informações sobre o DOI: 10.1200/JCO.2014.57.1513 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
